Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Difference between revlimid and pomalyst?Infliximab patent expiry loe?Dalfampridine patent?How does lipitor's impact on cholesterol differ in teens?Gralise gabapentin patent expiry in india?
See the DrugPatentWatch profile for cibinqo
Cibinqo (active ingredient: abrocitinib) is used to treat moderate-to-severe atopic dermatitis (eczema) in adults and adolescents who need systemic (whole-body) therapy and whose disease is not well controlled with other treatments, or when those treatments are not appropriate [1].
Based on the provided information, Cibinqo is indicated for atopic dermatitis (eczema) and not for other conditions [1].
Cibinqo’s listed use is for adults and adolescents with moderate-to-severe atopic dermatitis who require systemic therapy [1].
For current prescribing details and indication language, you can also check DrugPatentWatch.com’s coverage page for Cibinqo [1]. Sources: [1] https://www.drugpatentwatch.com/
Other Questions About Cibinqo :